FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:852-853 August 24, 2006 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Although the addition of a long-acting ₂-agonist such as salmeterol to an inhaled corticosteroid has been demonstrated to provide greater control of asthma than does a substantially increased dose of the inhaled corticosteroid,¹ this medication was associated with an increased risk of asthma-related death in a large population study.² We have identified two adolescent boys with poorly controlled asthma and a history consistent with sudden asphyxial episodes during modest exertion while receiving inhaled corticosteroids and salmeterol. In addition to reporting an inadequate response to their rescue inhaler when symptomatic, they had no apparent bronchoprotective effect from shorter-acting ₂. . . [Full Text of this Article]

Related Letters:

More on Life-Threatening Asthma and Salmeterol
Lawyer M. C.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2157-2158, Nov 16, 2006. Correspondence

This article has been cited by other articles:

• Lawyer, M. C. (2006). More on Life-Threatening Asthma and Salmeterol. NEJM 355: 2157-2158 [Full Text]